NGM
Morgan Stanley’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-155,462
| Closed | -$247K | – | 8072 |
|
|
2024
Q1 | $247K | Sell |
155,462
-165,460
| -52% | -$263K | ﹤0.01% | 5649 |
|
|
2023
Q4 | $276K | Sell |
320,922
-156,318
| -33% | -$134K | ﹤0.01% | 5824 |
|
|
2023
Q3 | $511K | Sell |
477,240
-420,892
| -47% | -$450K | ﹤0.01% | 5163 |
|
|
2023
Q2 | $2.33M | Buy |
898,132
+41,823
| +5% | +$108K | ﹤0.01% | 4322 |
|
|
2023
Q1 | $3.49M | Buy |
856,309
+194,276
| +29% | +$793K | ﹤0.01% | 4074 |
|
|
2022
Q4 | $3.32M | Buy |
662,033
+114,974
| +21% | +$577K | ﹤0.01% | 4101 |
|
|
2022
Q3 | $7.16M | Sell |
547,059
-44,165
| -7% | -$578K | ﹤0.01% | 3322 |
|
|
2022
Q2 | $7.58M | Buy |
591,224
+10,520
| +2% | +$135K | ﹤0.01% | 3364 |
|
|
2022
Q1 | $8.86M | Buy |
580,704
+286,737
| +98% | +$4.37M | ﹤0.01% | 3049 |
|
|
2021
Q4 | $5.21M | Buy |
293,967
+151,219
| +106% | +$2.68M | ﹤0.01% | 3679 |
|
|
2021
Q3 | $3M | Sell |
142,748
-24,027
| -14% | -$505K | ﹤0.01% | 4231 |
|
|
2021
Q2 | $3.29M | Sell |
166,775
-75,795
| -31% | -$1.49M | ﹤0.01% | 4197 |
|
|
2021
Q1 | $7.05M | Buy |
242,570
+32,287
| +15% | +$939K | ﹤0.01% | 3045 |
|
|
2020
Q4 | $6.37M | Buy |
210,283
+57,234
| +37% | +$1.73M | ﹤0.01% | 3003 |
|
|
2020
Q3 | $2.44M | Sell |
153,049
-32,472
| -18% | -$517K | ﹤0.01% | 3478 |
|
|
2020
Q2 | $3.66M | Buy |
185,521
+182,634
| +6,326% | +$3.61M | ﹤0.01% | 2993 |
|
|
2020
Q1 | $35K | Sell |
2,887
-42,864
| -94% | -$520K | ﹤0.01% | 5592 |
|
|
2019
Q4 | $846K | Buy |
45,751
+24,029
| +111% | +$444K | ﹤0.01% | 4629 |
|
|
2019
Q3 | $301K | Buy |
21,722
+21,697
| +86,788% | +$301K | ﹤0.01% | 4930 |
|
|
2019
Q2 | $0 | Buy |
+25
| New | – | ﹤0.01% | 6794 |
|